{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T03:59:49Z","timestamp":1648612789744},"reference-count":28,"publisher":"Japan Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1507\/endocrj.ej14-0194","type":"journal-article","created":{"date-parts":[[2014,9,17]],"date-time":"2014-09-17T02:02:44Z","timestamp":1410919364000},"page":"1213-1220","source":"Crossref","is-referenced-by-count":5,"title":["Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes"],"prefix":"10.1507","volume":"61","author":[{"given":"Shiko","family":"Asai","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Ohta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Sada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyasu","family":"Sasaoka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, University School of Toyama, Toyama 930-0194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Janka HU, Hessel F, Walzer S, M&atilde; Ller E (2007) Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes&mdash;a simulation with the Diabetes Mellitus Model (DMM). <i>Int J Clin Pharmacol Ther<\/i> 45: 623-630.","DOI":"10.5414\/CPP45623"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Pscherer S, Dietrich ES, Dippel FW,Neilson AR (2010) Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.<i> Int J Clin Pharmacol Ther<\/i> 48: 129-137.","DOI":"10.5414\/CPP48129"},{"key":"3","unstructured":"3. Ohtani T, Ito T (2011) Safty and effectiveness of BOT (basal supported oral therapy) using insulin glargine in Japanese patients with type 2 diabetes-results from postmarketing surveillance of insulin glargine (ALOHA study). <i>Shinyaku to Rinsho (J New Rem Clin) <\/i>60: 458-475 (In Japanese)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ohta A, Kato H, Murayama K, Hashimoto E, Murakami M,<i> et al.<\/i> (2014) Effect of insulin glargine on endogenous insulin secretion and beta-cell function in Japanese type 2 diabetic patients using oral antidiabetic drugs. <i>Endocr J <\/i>61: 13-18.","DOI":"10.1507\/endocrj.EJ13-0304"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. <i>JAMA<\/i> 298: 194-206.","DOI":"10.1001\/jama.298.2.194"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Neumiller JJ, Wood L, Campbell RK (2010) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. <i>Pharmacotherapy<\/i> 30: 463-484.","DOI":"10.1592\/phco.30.5.463"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Takahara M, Shiraiwa T, Kaneto H, Katakami N, Matsuoka TA, <i>et al.<\/i> (2012) Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. <i>Endocr J <\/i>59: 1131-1136.","DOI":"10.1507\/endocrj.EJ12-0220"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA,<i> et al.<\/i> (2010) Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. <i>Diabetes Care<\/i> 33: 1509-1515.","DOI":"10.2337\/dc09-2191"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Takeda Y, Fujita Y, Honjo J, Yanagimachi T, Sakagami H,<i> et al.<\/i> (2012) Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.<i> Diabetologia<\/i> 55: 404-412.","DOI":"10.1007\/s00125-011-2365-4"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mu J, Woods J, Zhou YP, Roy RS, Li Z, et al. (2006) Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.<i> Diabetes<\/i> 55: 1695-1704.","DOI":"10.2337\/db05-1602"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Pf&uuml;tzner A, Pf&uuml;tzner AH, Larbig M, Forst T (2004) Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. <i>Diabetes Technol Ther<\/i> 6: 405-412.","DOI":"10.1089\/152091504774198124"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Pscherer S, Larbig M, von Stritsky B,Pf&uuml;tzner A, Forst T(2012) In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment. <i>J Diabetes Sci Technol<\/i> 6: 634-640.","DOI":"10.1177\/193229681200600318"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Pistrosch F, K&ouml;hler C, Schaper F, Landgraf W, Forst T, <i>et al.<\/i> (2013) Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes. <i>Acta Diabetol <\/i>50: 587-595.","DOI":"10.1007\/s00592-012-0451-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, et al. (2010) Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. <i>Endocr J<\/i> 57: 383-394.","DOI":"10.1507\/endocrj.K09E-272"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Katsuno T, Ikeda H, Ida K,Miyagawa J, Namba M (2013) Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. <i>Endocr J <\/i>60: 733-742.","DOI":"10.1507\/endocrj.EJ12-0293"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, <i>et al. <\/i>(2012) Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. <i>J Clin Endocrinol Metab <\/i>97: 2818-2826.","DOI":"10.1210\/jc.2012-1205"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Aaboe K, Knop FK, Vilsb&oslash;ll T, Deacon CF, Holst JJ, <i>et al.<\/i> (2010) Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. <i>Diabetes Obes Metab<\/i> 12: 323-333.","DOI":"10.1111\/j.1463-1326.2009.01167.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mari A, Scherbaum WA, Nilsson PM, Lalanne G, Schweizer A, <i>et al.<\/i> (2008) Characterization of the influence of vildagliptin on model-assessed &beta;-cell function in patients with type 2 diabetes and mild hyperglycemia. <i>J Clin Endocrinol Metab<\/i> 93:103-109.","DOI":"10.1210\/jc.2007-1639"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, <i>et al. <\/i>(2010) Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. <i>Metabolism<\/i> 59: 887-895.","DOI":"10.1016\/j.metabol.2009.10.007"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Derosa G, Carbone A, Franzetti I, Querci F, Fogari E,<i> et al. <\/i>(2012) Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, \u03b2-cell function and insulin resistance in type 2 diabetic patients. <i>Diabetes Res Clin Pract<\/i> 98:51-60.","DOI":"10.1016\/j.diabres.2012.05.022"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Bajaj M, Pratipanawatr T, Berria R, Pratipanawatr W, Kashyap S, <i>et al. <\/i>(2002) Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes.<i> Diabetes <\/i>51: 3043-3048.","DOI":"10.2337\/diabetes.51.10.3043"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Jovanovic A, Gerrard J, Taylor R (2009) The second-meal phenomenon in type 2 diabetes. <i>Diabetes Care<\/i> 32: 1199-1201.","DOI":"10.2337\/dc08-2196"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Bunck MC, Diamant M, Corn&eacute;r A, Eliasson B, Malloy JL, <i>et al. <\/i>(2009) One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. <i>Diabetes Care<\/i> 32: 762-768.","DOI":"10.2337\/dc08-1797"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P (2011) Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. <i>Diabetes Obes Metab<\/i> 13: 366-373.","DOI":"10.1111\/j.1463-1326.2011.01362.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Yamanouchi T, Ogata N, Tagaya T, T, Kawasaki T, Sekino N, <i>et al. <\/i>(1996) Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. <i>Lancet<\/i> 347: 1514-1518.","DOI":"10.1016\/S0140-6736(96)90672-8"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D,<i> et al. <\/i>(2008) Translating the A1C assay into estimated average glucose values. <i>Diabetes Care<\/i> 31: 1473-1478.","DOI":"10.2337\/dc08-0545"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Suwa T, Ohta A, Matsui T, Koganei R, Kato H, <i>et al. <\/i>(2010) Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). <i>Endocr J<\/i> 57: 135-140.","DOI":"10.1507\/endocrj.K09E-234"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Aso Y, Ozeki N, Terasawa T, Naruse R, Hara K, <i>et al. <\/i>(2012)Serum level of soluble CD26\/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and\/or sulfonylurea. <i>Transl Res<\/i> 159: 25-31.","DOI":"10.1016\/j.trsl.2011.09.005"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T20:33:25Z","timestamp":1498163605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/61\/12\/61_EJ14-0194\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej14-0194","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}